Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013 (2013), Article ID 582809, 16 pages
http://dx.doi.org/10.1155/2013/582809
Research Article

Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP

1Preclinical Parkinson’s Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, 1220 Capitol Court, Madison, WI 53715, USA
2Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI 53715, USA
3Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
4Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA
5School of Pharmacy, 777 Highland Avenue, University of Wisconsin-Madison, Madison, WI 53705, USA
6Department of Medical Physics, 1111 Highland Avenue, University of Wisconsin-Madison, Madison, WI 53705, USA

Received 20 April 2013; Revised 24 July 2013; Accepted 25 July 2013

Academic Editor: Paul Drew

Copyright © 2013 Christine R. Swanson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Table 1 lists the primers used in real-time quantitative PCR (RT-qPCR) in striatal and nigral tissue.

Supplementary Tables 2 and 3 list effects of LSN4862 on striatal and nigral mRNA expression.

Supplementary Figure 1. LSN862 confers neuroprotection against MPTP toxicity in ARE-hPAP mice.

Supplementary Figure 2. LSN862 does not affect striatal and nigral hPAP activity in ARE-hPAP mice.

  1. Supplementary Materials